Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tymazoline is an imidazoline derivative and a sympathomimetic agent structurally related to oxymetazoline and xylometazoline. It acts as a topical nasal decongestant, primarily used for the relief of nasal congestion associated with colds, allergies, or sinusitis. Tymazoline exerts its effect by stimulating alpha-adrenergic receptors in the nasal mucosa, leading to vasoconstriction of blood vessels and subsequent reduction in swelling and congestion. Its mechanism of action is similar to other imidazoline-based decongestants such as oxymetazoline[1][5][7]. Tymazoline has been marketed in some countries but is not widely available globally.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tymazoline.